MK-1045 for B-cell cancers like CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called MK-1045 for people with B-cell cancers such as CLL or SLL that have come back or stopped responding to other treatments. The study aims to see if MK-1045 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CLL or SLL that is active and has not responded to or has returned after previous treatment.
- Your cancer cells must have a protein called CD19 on them.
- If you have HIV, it must be well-controlled with medication.
- If you have had hepatitis B or C, the virus must be undetectable in your blood.
- You cannot have certain heart, brain, or nervous system conditions, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
This early study tests MK-1045 in people with precursor B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to earlier treatment. It may help shrink leukemia and improve remission in patients with limited options.
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Hear when a new Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.